Bifogade filer
Cantargia Q1 2023 - Strong results with IL1RAP-high patients
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2023-05-24 07:56:00
Redeye reviews Cantargia’s first quarter report. Since our last update (Q4 2022), important results have been published at the AACR meeting, demonstrating the superior efficacy of nadunolimab in pancreatic cancer patients with high levels of IL1RAP. The next step in the development of nadunolimab in pancreatic cancer will be a phase IIb study instead of the registrational Precision Promise. However, due to the longer development needed and other factors we lower our Base Case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/